In its new report, Technavio says the the global restless legs syndrome (RLS) market is expected to grow at a compound annual growth rate (CAGR) of 12% from 2015-2019.

The analysis draws attention towards the high unmet medical needs for patients suffering from this syndrome. The unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease, and currently marketed drugs offer only symptomatic relief. “Adverse effects caused by the use of available drugs creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption,” says Faisal Ghaus, vice president of Technavio, in a release.

The report also emphasizes the expected entry of drugs with multiple mechanisms and novel techniques. The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. “Serina’s drug SER-214 involves a water-soluble polymer based drug delivery technology that can be connected to the polymer and delivered to target specific receptors,” says Ghaus.